ABBV vs MELI: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and MercadoLibre, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
MercadoLibre, Inc. · Consumer Cyclical
$1,767.42
+41.4% upside to fair value
High Conviction
Grade A
QuantHub Verdict
MELI has more upside to fair value
(+41.4%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MELI |
| Current Price |
$208.05 |
$1,767.42 |
| Fair Value Estimate |
$217.50 |
$2,500.00 |
| Upside to Fair Value |
+4.5%
|
+41.4%
|
| Market Cap |
$367.9B |
$89.6B |
| Forward P/E |
14.9x
|
35.0x
|
| EV / EBITDA |
16.7x
|
18.5x
|
| Price / Sales |
6.1x
|
3.1x
|
| Price / FCF |
20.9x
|
8.9x
|
| Revenue Growth YoY |
+8.6%
|
+39.1%
|
| Gross Margin |
83.7%
|
44.5%
|
| Operating Margin |
34.7%
|
11.1%
|
| Return on Equity |
-129.24%
|
33.7%
|
| Dividend Yield |
3.2% |
0% |
| FCF Yield |
4.78%
|
12.1%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
MercadoLibre is the dominant e-commerce and fintech ecosystem across Latin America, operating the largest marketplace and digital payments platform in a region with 670M+ people where e-commerce penetration is still under 15%. Revenue grew 39% to $28.9B in FY2025 with $10.8B in free cash flow — a 12% FCF yield at current prices. The company is trading at its 5-year P/S minimum (3.1x) and P/FCF mi…
Accumulation Zones
| Metric |
ABBV |
MELI |
| Zone Low |
$163.13 |
$1,875.00 |
| Zone High |
$184.88 |
$2,125.00 |
| In Buy Zone? |
No
|
Yes
|